ANTIPROTOZOAL DRUGS MARKET REPORT OVERVIEW
-
.svg)
to learn more about this report
The global antiprotozoal drugs market size was USD 17250 million in 2021 and the market is projected to touch USD 22180 million by 2028, exhibiting a CAGR of 3.6% during the forecast period.
Antiprotozoal drugs are pharmaceuticals created with the intention of combating infections induced by protozoa, which are unicellular microorganisms capable of causing diverse illnesses in humans. These medications function by interrupting the life cycle or activities of protozoa, ultimately eradicating the infection from the body.
Antimalarial drugs are predominantly employed in the management of malaria, an illness triggered by the Plasmodium parasite and transmitted via the bites of infected mosquitoes. These medications are designed to address different phases of the parasite's life cycle, encompassing measures for preventing infection (prophylaxis), managing acute malaria episodes, and averting relapses.
COVID-19 Impact: Increased Awareness and Preparedness among Population to Fuel Market Growth
The pandemic has raised awareness about infectious diseases and the significance of preventive measures and treatments. This heightened awareness could indirectly enhance recognition and understanding of protozoal infections, potentially resulting in an uptick in demand for antiprotozoal drugs.
The global healthcare systems faced strain due to the COVID-19 pandemic, causing disruptions in routine medical services, including the diagnosis and treatment of non-COVID-19 conditions. Limited access to healthcare facilities and resources might have impeded prompt diagnosis and treatment of protozoal infections, potentially affecting the demand for antiprotozoal drugs.
LATEST TRENDS
"Drug Development and Innovation, Combination Therapies to Drive Market Growth"
Scientists are investigating novel drug targets in protozoal pathogens to create more potent treatments. This entails pinpointing crucial biological pathways or molecular structures specific to the parasites, which can be manipulated to interfere with their lifecycle or survival mechanisms. The advancement of screening technologies, including high-throughput and virtual screening, is expediting the discovery of fresh antiprotozoal compounds. These methodologies empower researchers to analyze extensive collections of chemical compounds or natural products to uncover potential drug candidates with antiprotozoal properties. Research into combination therapies comprising multiple antiprotozoal drugs aims to improve treatment effectiveness, lower the likelihood of drug resistance, and manage intricate infections caused by protozoa with multiple drug targets. These therapies may consist of established antiprotozoal drugs or innovative drug combinations.
ANTIPROTOZOAL DRUGS MARKET SEGMENTATION
-
to learn more about this report
By Type
Based on type the global antiprotozoal drugs market can be categorized into by Diseases, Amoebic Dysentery, Antimalarial Drug, Leishmaniasis & Chagas Diseas, by Drugs, Metronidazole, Atovaquone, Benznidazole, Dehydroemetine, Eflornithine, Emetine, Fenbendazole, Iodoquinol, Melarsoprol, and Others.
By Diseases
- Amoebic Dysentery: Medications intended for treating amoebic dysentery, induced by the Entamoeba histolytica parasite, work to eliminate the amoeba from the gastrointestinal tract, thereby relieving symptoms like diarrhea and abdominal discomfort. Metronidazole stands as a prevalent medication employed for this objective.
- Antimalarial Drug: Antimalarial drugs are formulated to address malaria, an illness instigated by Plasmodium parasites disseminated through mosquito bites. Medications like Atovaquone and Artemisinin derivatives are tailored to target multiple stages of the parasite's life cycle, encompassing prevention, management of acute episodes, and prevention of relapses.
- Leishmaniasis & Chagas Disease: Therapies for leishmaniasis and Chagas disease, brought on by Leishmania and Trypanosoma cruzi parasites correspondingly, strive to eradicate the parasites from the body. Benznidazole serves as a frequently prescribed medication for Chagas disease, whereas treatments for leishmaniasis encompass antimonials, Amphotericin B, and miltefosine.
By Drugs
- Metronidazole: With effectiveness spanning across a broad spectrum of protozoa, metronidazole is frequently administered for the treatment of infections like amoebiasis, giardiasis, and trichomoniasis.
- Atovaquone: Mainly employed in combination therapies for malaria treatment, this drug functions by disrupting the mitochondrial function within the parasite.
- Benznidazole: Benznidazole, utilized for Chagas disease treatment, operates by impeding the growth of Trypanosoma cruzi parasites.
- Dehydroemetine: Utilized in the treatment of amoebic dysentery, these medications function by hindering protein synthesis in Entamoeba histolytica parasites.
- Eflornithine: Employed in the treatment of African trypanosomiasis, commonly referred to as sleeping sickness, this medication functions by inhibiting the enzyme responsible for the proliferation of Trypanosoma brucei parasites.
- Emetine: Emetine, historically employed for treating amoebiasis—an infection caused by Entamoeba histolytica—works by impeding protein synthesis within the parasite, thereby facilitating its elimination from the body.
- Fenbendazole: While its primary use is as an anthelmintic, fenbendazole has demonstrated efficacy against specific protozoal infections, notably giardiasis.
- Iodoquinol: Iodoquinol, employed for amoebiasis treatment, functions by disturbing the metabolism of Entamoeba histolytica parasites.
- Melarsoprol: This medication is utilized for the treatment of advanced stages of African trypanosomiasis, albeit its usage is restricted due to severe adverse effects.
- Others: A variety of other medications, such as artemisinin derivatives, antimonials, and pentamidine, are employed for treating protozoal infections, with the choice contingent upon the particular disease and its severity.
By Application
Based on application the global antiprotozoal drugs market can be categorized into Hospital, and Clinic
- Hospital: Within the global antiprotozoal drugs market, the Hospital application segment pertains to the utilization of these medications within hospital environments. Here, patients with severe protozoal infections undergo intensive care and treatment. Hospitals typically dispense antiprotozoal drugs to individuals with intricate cases necessitating specialized medical supervision and monitoring.
- Clinic: The Clinic application segment encompasses the usage of antiprotozoal drugs in outpatient clinics or healthcare facilities. These clinics provide diagnostic services, consultations, and treatments for a range of medical conditions, including milder protozoal infections. Antiprotozoal drugs may be prescribed in clinic settings for patients needing less intensive care or follow-up treatment.
DRIVING FACTORS
"Disease Burden to Boost the Market"
The prevalence of protozoal infections like malaria, leishmaniasis, and amoebiasis remains a key driver for the antiprotozoal drugs market growth.
"Research and Development to Expand the Market"
Continuous investments in research and development, focused on uncovering novel drug candidates and enhancing current therapies, play a pivotal role in driving market expansion.
RESTRAINING FACTOR
"Drug Resistance to Potentially Impede Market Growth"
The rise of drug-resistant strains among protozoal parasites presents a notable hurdle to the effectiveness of current antiprotozoal drugs, thereby constraining treatment choices and prompting the exploration of alternative therapies.
ANTIPROTOZOAL DRUGS MARKET REGIONAL INSIGHTS
-
to learn more about this report
The market is primarily segregated into Europe, Latin America, Asia Pacific, North America and Middle East & Africa.
"North America to Dominate the Market owing to pharmaceutical research and development"
In North America, the antiprotozoal drugs market share is influenced by several factors. This includes the prevalence of malaria in specific regions, as well as a notable emphasis on researching and developing new drug formulations. The United States, as a key player in pharmaceutical research and development, holds a significant market share, contributing substantially to advancements in antiprotozoal drug discovery and development. Moreover, government initiatives and funding directed towards healthcare and disease control programs play a pivotal role in shaping market dynamics.
KEY INDUSTRY PLAYERS
"Key Industry Players Shaping the Market through artemisinin-based combination therapies"
The antiprotozoal drugs market features numerous influential industry players actively involved in researching, developing, manufacturing, and distributing antiprotozoal medications. Novartis stands out as a prominent global pharmaceutical entity with a robust footprint in this market segment. Renowned for its specialization in antiprotozoal drugs, Novartis manufactures a range of medications targeting diseases like malaria, notably including artemisinin-based combination therapies (ACTs).
List of Market Players Profiled
- Sanofi (France)
- Pfizer (U.S.)
- Profounda (U.S.)
- Wanlong (China)
- Fangsheng (China)
INDUSTRIAL DEVELOPMENT
December 2023: The demand for antiprotozoal drugs is projected to increase in the foreseeable future, driven by the expansion of healthcare infrastructure, escalating healthcare expenditure, and heightened awareness of such diseases. Additionally, advancements in drug delivery systems and a surge in research endeavors aimed at pioneering innovative treatment approaches are bolstering the growth trajectory of the antiprotozoal drugs market.
REPORT COVERAGE
The future demand for antiprotozoal drugs market is covered in this study. The Research report includes the Increased Awareness and Preparedness due to the Covid-19 Impact. The report covers the latest trends in Drug Development and Innovation. The paper includes a segmentation of the antiprotozoal drugs market. The research paper includes the driving factors that are Disease Burden to Fuel Market Growth. The report also covers information on Regional Insights where the region which has emerged leading market for antiprotozoal drugs.
| REPORT COVERAGE | DETAILS |
|---|---|
Market Size Value In |
US$ 17250 Million in 2021 |
Market Size Value By |
US$ 22180 Million by 2028 |
Growth Rate |
CAGR of 3.6% from 2021 to 2028 |
Forecast Period |
2021-2028 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the antiprotozoal drugs market expected to touch by 2028?
The global antiprotozoal drugs market is expected to reach 22180 million by 2028.
-
What CAGR is the antiprotozoal drugs market expected to exhibit by 2028?
The antiprotozoal drugs market is expected to exhibit a CAGR of 3.6% by 2028.
-
Which are the driving factors of the antiprotozoal drugs market?
Disease Burden, and Research and Development are some of the driving factors of antiprotozoal drugs market.
-
What are the key antiprotozoal drugs market segments?
The key Antiprotozoal Drugs market segmentation that you should be aware of, which include, Based on type the antiprotozoal drugs market is classified as by Diseases, Amoebic Dysentery, Antimalarial Drug, Leishmaniasis & Chagas Diseas, by Drugs, Metronidazole, Atovaquone, Benznidazole, Dehydroemetine, Eflornithine, Emetine, Fenbendazole, Iodoquinol, Melarsoprol, and Others. Based on application antiprotozoal drugs market is classified as Hospital, and Clinic.
